2013
The Company Is Founded
Sudair Pharma Company was established in February 2013.
Advancing healthcare through scientific excellence, advanced manufacturing, and innovation — while contributing to the localization of pharmaceutical production in Saudi Arabia.
Our journey is built on a strong purpose, a passion for excellence, and a commitment to creating a healthier tomorrow.
We continue to grow with innovation, integrity, and impact.
Our Journey
From our foundation in 2013 to becoming a regional leader in pharmaceutical manufacturing, our journey is built on milestones that drive progress and improve lives.
2013
Sudair Pharma Company was established in February 2013.
2015
Construction commenced on our first dedicated oncology manufacturing facility.
2017
Signed our first technology and knowledge transfer agreement for oncology medicines.
2018
Registered our first portfolio of 11 products with the Saudi Food and Drug Authority (SFDA).
2019
Expanded into the Bahraini market with our oncology portfolio.
2020
Registered 31 new products, increasing the portfolio to 45 products, and expanded into the United Arab Emirates.
2021
Registered 16 additional products, reaching 61 registered products, and expanded into new therapeutic areas.
2022
Portfolio reached 67 products across oncology, respiratory, neurology, and anti-infective therapeutic areas.
2023
Registered 14 new products, bringing the portfolio to 81 registered products, while expanding local pharmaceutical manufacturing.
2024
Registered 20 additional products, reaching 95 products, and launched the major expansion of the Sudair Manufacturing Complex.
2025
Construction commenced on our dedicated insulin manufacturing facility for end-to-end insulin production.
Guided by a clear purpose and a shared vision, we are committed to improving lives through quality, innovation, and integrity.
Improves lives through localising advanced therapies
Enhancing our community’s access high-quality medicinal products through our professional team, to localise and to develop cutting edge manufacturing technologies.
Therapeutic Areas
From oncology and hematology to respiratory, neurology, cardiometabolic and rare disease therapies — manufactured and supplied to international quality standards.
Advancing
Health.
Transforming
Lives.
Sudair Pharma signed two major agreements during the Global Health Exhibition 2025: a cooperation agreement with NUPCO to enhance the national pharmaceutical supply chain, and a localization agreement with the Local Content & Government Procurement Authority to manufacture Bilotinib locally. These agreements reinforce Sudair Pharma’s commitment to national self-sufficiency and Vision 2030 goals in pharmaceutical manufacturing.
Sudair Pharma was honored to welcome His Excellency the Minister of Health, Fahad Al-Jalajel, during its participation in the Global Health Exhibition 2025. The visit highlighted the Kingdom’s commitment to strengthening national pharmaceutical manufacturing and advancing a sustainable healthcare system. Several senior officials and leaders also visited the booth, underscoring Sudair Pharma’s growing impact in shaping the future of Saudi healthcare.
Sudair Pharma participated in the Global Health Exhibition 2025, showcasing advanced national pharmaceutical capabilities and highlighting the company’s contribution to strengthening Saudi Arabia’s healthcare ecosystem. The SPC booth attracted significant interest and served as a platform for strategic discussions and industry engagement.